Prelude Therapeutics (NASDAQ: PRLD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Prelude Therapeutics reported 0 open-market sales and 4 open-market purchases of 5,630,630 shares ($25.0m), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 27 April 2026 | Shah Rajeev M. | — | Other | −1,407,000 | — | 6,475,882 | Form 4 |
| 21 April 2026 | OrbiMed Genesis GP LLC | Director | Open-market purchase | +1,689,189 | $4.44 | 11,808,945 | Form 4 |
| 21 April 2026 | OrbiMed Genesis GP LLC | Director | Open-market purchase | +1,126,126 | $4.44 | 1,126,126 | Form 4 |
| 21 April 2026 | Bonita David P | Director | Open-market purchase | +1,689,189 | $4.44 | 11,808,945 | Form 4 |
| 21 April 2026 | Bonita David P | Director | Open-market purchase | +1,126,126 | $4.44 | 1,126,126 | Form 4 |
| 4 October 2025 | Huang Jane | President, CMO | Option exercise | +9,375 | — | 90,272 | Form 4 |
| 4 October 2025 | Huang Jane | President, CMO | Shares withheld for tax | −3,355 | $1.47 | 86,917 | Form 4 |
| 4 July 2025 | Huang Jane | President, CMO | Option exercise | +9,375 | — | 84,252 | Form 4 |
| 4 July 2025 | Huang Jane | President, CMO | Shares withheld for tax | −3,355 | $0.79 | 80,897 | Form 4 |
| 4 April 2025 | Huang Jane | President, CMO | Option exercise | +9,375 | — | 78,232 | Form 4 |
| 4 April 2025 | Huang Jane | President, CMO | Shares withheld for tax | −3,355 | $0.68 | 74,877 | Form 4 |
| 25 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +675,000 | $0.69 | 1,999,296 | Form 4 |
| 25 March 2025 | Combs Andrew | Chief Chemistry Officer | Open-market purchase | +100,000 | $0.69 | 480,123 | Form 4 |
| 21 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +15,000 | $0.73 | 1,324,296 | Form 4 |
| 20 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +5,416 | $0.73 | 1,309,296 | Form 4 |
| 17 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +9,106 | $0.75 | 1,303,880 | Form 4 |
| 14 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +29,999 | $0.75 | 1,294,774 | Form 4 |
| 13 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +50,000 | $0.72 | 1,264,775 | Form 4 |
| 12 March 2025 | Vaddi Krishna | CEO | Open-market purchase | +47,500 | $0.71 | 1,214,775 | Form 4 |
| 4 January 2025 | Huang Jane | President, CMO | Option exercise | +9,375 | — | 72,716 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Prelude Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.